-
Innovent Biologics Sees 6.7% Revenue Increase in 2022 Amidst R&D Growth and Product Expansion
•
Biopharmaceutical company Innovent Biologics Inc., (HKG: 1801), has reported revenues of RMB 4.55 billion (USD 660.6 million) for 2022, reflecting a 6.7% year-on-year (YOY) increase. Product revenues specifically reached RMB 4.139 billion (USD 600.9 million), up 3.4% YOY. This growth was driven by increased volumes and new product revenues, despite…
-
Burning Rock Reports Q4 2022 Revenue Dip but 10.9% Full-Year Growth
•
Guangzhou-based medical device company Burning Rock (NASDAQ: BNR) has released its financial results for the fourth quarter of 2022. The company reported Q4 revenues of CNY 142.2 million (USD 20.6 million), marking a 3.5% decrease year-on-year (YOY). However, for the full 12 months, revenues showed a positive trend, increasing by…
-
Hansoh Pharmaceutical Reports 2022 Revenues and Highlights Growth in Innovative Drugs
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has released its financial report for 2022. As of December 31, 2022, the company reported revenues of RMB 9.382 billion (USD 1.362 billion), a decrease of 5.6% year-on-year (YOY). Despite this, the sales revenue of innovative drugs reached RMB 5.006 billion (USD…
-
Fosun Pharma Reports 12.66% YOY Revenue Growth and Increased R&D Investment in 2022 Financial Report
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report for 2022, highlighting revenues of RMB 43.952 billion (USD 6.381 billion), marking a 12.66% increase year-on-year (YOY). The company’s net profits also saw a significant rise, reaching RMB 3.873 billion (USD 562.4 million), up 18.17%…
-
Grand Pharmaceutical Group Reports 15.1% Revenue Growth in 2022 Financials
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) published its 2022 financials, reporting revenues of HKD 9.562 billion (USD 1.2 billion) over the 12 months, marking a 15.1% increase year-on-year (YOY). The net profit attributable to equity holders reached HKD 2.14 billion (USD 272 million), up 15.4% YOY. The company invested…
-
Ascentage Pharma’s 2022 Revenue Soars with Olverembatinib Sales
•
China-based Ascentage Pharma (HKG: 6855) has announced its 2022 financial results, marking the first year of commercial sales for olverembatinib (HQP1351). The third-generation BCR-ABL-targeted tyrosine kinase inhibitor (TKI) was approved in November 2021 to treat TKI-resistant chronic-phase CML (CML-CP) or accelerated-phase CML (CML-AP) with the T315I mutation. The company recorded…
-
Ping An Good Doctor Reports Revenue Decline but Medical Services Growth in 2022
•
China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as Ping An Good Doctor, released its 2022 financial report. The company recorded revenues of RMB 6.16 billion (USD 902.9 million) throughout the year, marking a 16.01% decrease year-on-year (YOY). Losses narrowed to RMB 611 million (USD 89.5…
-
JD Healthcare Reports 52.3% Revenue Growth in 2022 Financial Report
•
JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), released its 2022 financial report, showing total revenues of RMB 46.7 billion (USD 6.84 billion), a 52.3% increase year-on-year (YOY). As of December 31, 2022, the platform had more than 154 million annual active users, with healthcare daily inquiries…
-
WuXi Biologics Reports 48.4% Revenue Growth in 2022 Financial Report
•
China-based WuXi Biologics (HKG: 2269) released its 2022 financial report for the period ending December 31, 2022. The Contract Development and Manufacturing Organization (CDMO) reported total income of RMB 15.27 billion (USD 2.237 billion), marking a 48.4% increase year-on-year (YOY). Net profits also rose by 47.1% YOY, reaching RMB 5.05…
-
3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials
•
China-based 3SBio Inc. (HKG: 1530) released its 2022 financial report, recording revenues of RMB 6.859 billion (USD 995.9 million), a 7.5% increase year-on-year (YOY). Net profits reached RMB 2.163 billion (USD 314 million), up 25.2% YOY. This marks a significant milestone in the company’s ongoing growth and expansion. Core Product…
-
WuXi AppTec Reports 71.8% Revenue Growth in 2022 Financials
•
China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) released its 2022 financial report, recording revenues of RMB 39.355 billion (USD 5.72 billion), a 71.8% increase year-on-year (YOY). Net profits also grew significantly, reaching RMB 8.814 billion (USD 1.28 billion), up 72.9% YOY. This marks a substantial milestone in the…
-
Ping An Life Insurance Reports Steady Profit Growth and Expands Managed Care Services
•
Ping An Life Insurance Company of China Ltd released its 2022 financial report, recording RMB 148.365 billion (USD 21.485 billion) in operating profits, up 0.3% year-on-year (YOY). The company also reported RMB 107.432 billion (USD 15.55 billion) in net profits and RMB 83.774 billion (USD 12.13 billion) in net profits…
-
Akeso Biopharma Reports 422% Increase in Product Sales, Boosted by Cadonilimab and Penpulimab
•
China-based Akeso Biopharma (HKG: 9926) released its 2022 financial report, highlighting significant growth in product sales. The company reported RMB 1.104 billion (USD 159.97 million) in product sales, representing a 422% year-on-year (YOY) increase. Product Sales and Market ApprovalsThe innovative bispecific antibody cadonilimab (AK104), targeting programmed death-1 (PD-1) and cytotoxic…
-
CStone Pharmaceuticals Reports 97.54% Revenue Growth in 2022, Driven by Drug Sales and Licensing Fees
•
China-based CStone Pharmaceuticals (HKG: 2616) released its 2022 financial report, recording total revenues of RMB 481.4 million (USD 69.78 million), marking a 97.54% year-on-year (YOY) increase. This growth was primarily driven by drug sales and licensing fees for Cejemly (sugemalimab). Commercial revenues reached RMB 394.1 million (USD 57.1 million), up…
-
Merck Reports 12.9% Sales Growth in 2022 Annual Report
•
German major Merck (NYSE: MRK) released its 2022 annual report this week, showing a robust expansion in global net sales. The company reported a 12.9% year-on-year (YOY) increase to EUR 22.2 billion (USD 23.6 billion), driven by growth across all business sectors. This performance underscores Merck’s continued strength in the…
-
Zai Lab Reports 2022 Financial Results with Revenue Growth
•
China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) has announced its full-year 2022 financial results, along with recent product highlights and corporate updates. The company reported total revenues of USD 215 million for 2022, marking an increase of 49% compared to 2021. This included total revenues of USD 62.6 million…
-
BeiGene Reports Outstanding Q4 and Full-Year 2022 Financial Results
•
BeiGene, Ltd. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has released financial results for the Q4 and full-year 2022 periods, along with recent business highlights and upcoming milestones. Revenues reached USD 380.1 million in Q4, up 72.3%, and USD 1.4 billion for the full 12 months, up 97.9%. CEO John Oyler…
-
Viatris Reports Q4 2022 Results, Highlights China Growth
•
US-based generics giant Viatris Inc. (NASDAQ: VTRS) has released its Q4 2022 financial report. The firm reported a 2% year-on-year (YOY) fall in net sales to USD 16.2 billion. The decrease was partly attributed to the USD 3 billion sale of Viatris’ biosimilars business to India-based Biocon Biologics Ltd, a…
-
HutchMed Reports 2022 Financial Results with Revenue Growth
•
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has released its financial results for the year ended December 31, 2022, alongside updates on key clinical and commercial developments. Revenues for the year ending December 31, 2022, were USD 426.4 million, compared to USD 356.1 million in 2021, primarily driven by…
-
FibroGen Reports Q4 2022 Financial Results with Revenue Growth
•
US-based FibroGen Inc. (FGEN) has released its Q4 2022 financial results. The company reported global revenues of USD 34.4 million in Q4, up from USD 16.4 million a year ago. For the 12 months, revenues reached USD 140.7 million, down from USD 235.3 million in 2021, when revenues were boosted…
